Bristol Myers Squibb (BMY) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Bristol Myers Squibb (BMY)

58.56

+1.04 (1.81%)

as of Jun 29, 2026, 8:00:00 pm Market Open.

160 watching

Investor Insights

Jun 29, 2026, 12:00 am

This summary was created by AI, based on 8 opinions in the last 12 months.

Bristol Myers Squibb (BMY-N) has received mixed reviews from experts, indicating potential strengths in its drug pipeline and dividends but also raising concerns about disappointing sales in certain areas, particularly regarding its Cobenfy drug. Some experts emphasize the company's growth portfolio, which has shown an impressive 18% year-over-year increase, while others voice caution due to declining sales from its legacy drugs. Despite some hesitations, recent earnings results exceeded expectations, with EPS and sales both surpassing estimates, leading to a raised revenue guidance for 2025. The sentiment suggests that the stock may have a chance to rebound if newer products continue to outperform older ones, though individual opinions vary significantly, highlighting a diversity of perspectives on the future performance of the stock.

Consensus

Mixed

Valuation

Undervalued

Similar

Lilly,LLY

DON'T BUY

Has had a lot of problems. Starting to clear up, but will take awhile.

WEAK BUY

DON'T BUY

Has had problems in manufacturing, shipping and FDA approvals. Exoects slow earnings growth.

BUY

Likes the valuations. Good balance sheet and good earnings.

BUY

Looks cheap. There is an SEC investigation going on.

DON'T BUY

Now is a good time for drug stocks, but this company has corporate problems.

BUY

9.25% dividend. Has been hit hard. Stable cash flow.

TOP PICK

Has been oversold. Very cheap. Could be a takeover.

DON'T BUY

Could drop. Prefers generic drugs.

BUY

Good drug company, but had difficulties getting FDA approvals. Good dividend. Cheap.

BUY

Made some poor moves. Still a triple A company.

PAST TOP PICK

(Was a top pick on May 23. Down 31%). Fell with health care. Price looks very good.

BUY

Trading at 5 X Book. Good dividends. New drug has approval.

BUY

Likes the drug sector. Prefers Pfizer.

DON'T BUY

Doesn't expect much growth, plus there are some issues.

Showing 196 to 210 of 221 entries

Most Recent Experts

Joe Terranova

Virtus Investment Partners

Stephanie Link, Chief investment strategist, Hightower

Hightower

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Jim Lebenthal

Cerity Partners

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Bristol Myers Squibb (BMY)